CAS: 1190-63-2; Hexadecyl Octadecanoate

上下游产品

CAS号36653-82-4 十六醇 | CAS号57-11-4 硬脂酸 | CAS号112-76-5 十八碳酰氯 | CAS号544-77-4 1-碘十六烷 | CAS号3507-99-1 硬脂酸银 | CAS号544-77-4 1-碘十六烷 | CAS号629-73-2 1-十六烯 | CAS号57-11-4 硬脂酸 | CAS号112-63-0 亚油酸甲酯 | CAS号112-61-8 硬脂酸甲酯 | CAS号112-82-3 溴代十六烷 | CAS号4860-03-1 氯代十六烷

📜1-十六烷醇,硬脂酸置于silica Gel-Immobilized Perchloric Acid体系中,化学反应 10.0H,以95%的收率获得十八烷酸十六烷基酯
参考文献:固定在固体载体上的质子酸是一种极其有效的可循环使用的催化剂体系,可直接和原子经济地将醇与醇酯化
标题:固定在固体载体上的质子酸是一种极其有效的可循环使用的催化剂体系,可直接和原子经济地将醇与醇酯化
摘要:据报道,通过容易制备的固定在硅胶上的高氯酸催化剂体系(hclo 4-Sio 2)催化等摩尔量的羧酸与醇的直接缩合,酯化反应既方便又清洁.已经实现了芳基,杂芳基,苯乙烯基,芳基烷基,烷基,环烷基和长链脂族羧酸与伯/仲烷基/环烷基,烯丙基,炔丙基和长链脂族醇的直接缩合以提供相应的酯高产.手性醇和n-T-Boc保护的手性氨基酸也导致与代表性的羧酸或醇形成酯,而没有竞争性的n-T-Boc对产品的光学纯度的脱保护和有害作用,表明该方法的温和性和化学选择性.长链(> C 10)酸和醇的酯以高收率获得.催化剂被回收和再循环而没有明显的活性损失.酯化工艺的工业应用通过布洛芬前药和几种商业调味剂的合成得到证明.其他质子酸如h 2 So 4,Hbr的,Tfoh,Hbf 4相比的hclo和tfa被吸附在硅胶上的是不太有效4-Sio 2以下的顺序的hclo 4-Sio 2 »ħ 2So 4-Sio
Doi:10.1021/jo900614S

专利信息

专利号:US-2006287520-A1
优先权日:2005-05-16
标 题 :Synthesis of salinosporamide A and analogues thereof
发明人：DANISHEFSKY SAMUEL J; ENDO ATSUSHI
权利人:DANISHEFSKY SAMUEL J; ENDO ATSUSHI
摘要:A novel synthesis of salinosporamide A is provided. Salinospoamide A as well as structurally related natural products, omuralide and lactacystin, have been shown to be proteasome inhibitors. Therefore, these compounds as well as analogues of these natural products may be useful in the treatment of proliferative diseases such as cancer, autoimmune diseases, diabetic retinopathy, etc. The invention provides for the synthesis of salinosporamide A as well as analogs thereof using a convenient point for derivatization of the bicyclic core. Pharmaceutical compositions and method of using the inventive compounds are also provided.

专利号:WO-2012047907-A9
优先权日:2010-10-04
标题 :Synthesis of c5-substituted tetracyclines, uses thereof, and intermediates thereto
发明人：MYERS ANDREW G; WRIGHT PETER M; HECKER EVAN
权利人:HARVARD COLLEGE; MYERS ANDREW G; WRIGHT PETER M; HECKER EVAN
摘要:The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides more efficient routes for preparing the enone intermediate and allows for a wide variety of substituents at position 5 of the tetracycline ring system.

专利号:US-6579725-B1
优先权日:1999-03-05
标题 :Linkers for synthesis of oligosaccharides on solid supports
发明人：SEEBERGER PETER H; ANDRADE RODRIGO B
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The present invention relates to versatile linkers for tethering a molecule to a solid support, e.g., for tethering a monomer, oligomer or polymer to a solid support, which are stable to a wide range of reaction conditions, but can be cleaved under well-defined conditions, thereby liberating the molecule from the solid support. Preferably, the linkers are used to tether to the solid support unprotected, partially-protected or fully-protected monosaccharides or oligosaccharides, or unprotected, partially-protected or fully-protected glycoconjugates. The linkers of the present invention may be used to tether to solid supports building blocks useful in the assembly of libraries of other types of small molecules. The present invention also relates to a molecule or plurality of molecules tethered to the solid support via a linker or linkers of the present invention. The present invention also relates to processes for synthesizing molecules, e.g., monomers, oligomers or polymers, on a solid support, wherein a starting material in the synthesis of the molecule, intermediates in the synthesis of the molecule, and the molecule itself are tethered to the solid support during the process via one of the linkers of the present invention. In certain processes of the present invention, the molecule is liberated from the solid support by cleavage of the linker of the present invention.

专利号:US-2009221568-A1
优先权日:2005-11-04
标题:Synthesis of Inhibitors of FtsZ
发明人：SHAW JARED; URGAONKAR SAMEER; RAYCHAUDHURI DEBABRATA; LA PIERRE HENRY
权利人:SHAW JARED; URGAONKAR SAMEER; RAYCHAUDHURI DEBABRATA; LA PIERRE HENRY
摘要:FtsZ, the bacterial analog of tubulin, is a promising new target for developing new antibiotics. It has been shown that polyphenols inhibit the GTPase activity of FtsZ, thereby inhibiting Z-ring formation during mitosis. The present invention provides novel polyphenols compounds, which can be accessed by the synthesis of dichamametin and 2′″-hydroxy-5″-benzylisouvarinol-B as described herein. These novel compounds are useful in treating infections, particularly infections caused by gram-positive organisms. Methods of preparing the inventive compounds are also provided. The compounds are prepared by the benzylation of pinocembrin or chrysin core structure. Pharmaceutical compositions and method of using the compounds to treat disease are also provided. These compounds may be screened for antimicrobial activity as well as other biological activities such as anti-neoplastic, anti-inflammatory, immunosuppressive, and cytotoxic activity.

专利号:US-2014255328-A1
优先权日:2013-03-11
标 题:Hydrothermal Synthesis of Zinc Phlogopite
发明人：MCGUIRE MEAGHAN CLARK; BULL IVOR; JOHNSON GEOFFREY MARK
权利人:BASF SE
摘要:This invention relates to a synthetically derived zinc phlogopite platelets, of superior platelet diameter, effect pigments comprising such synthetically derived platelets and methods of forming said substrates. More specifically the disclosure describes an improved hydrothermal synthesis of zinc phlogopite suitable as a platelets for interference pigments, barrier and flame retardant applications.

专利号:US-9597327-B2
优先权日:2005-05-25
标 题:Synthesis of (R)-N-methylnaltrexone
发明人：DOSHAN HAROLD D; PEREZ JULIO
权利人:PROGENICS PHARM INC
摘要:This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.